NEW YORK--(BUSINESS WIRE)--Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system related edema, today announced that the Company issued an end-of-first-quarter report.
Highlights of the report include six-month data from its Phase 2 randomized, double blind trial of the drug CIRARA™ in large hemispheric infarctions, adjudicated neurological mortality findings, and results of an analysis on patients 70 and younger.
